Belite Bio, Inc (BLTE) is in Healthcare, Biotechnology, based in United States, listed on NasdaqCM. Market cap 6.14B USD. 52-week range 77.64 to 200.00 USD. Data as of 2026-10-09.
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding ...